AlphaCentric Life Sciences and Healthcare Fund Class C
LYFCX
NASDAQ
Weiss Ratings | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Weak | |||
Reward Grade | D+ | |||
Risk Index | Weak | |||
Risk Grade | D+ | |||
Company Info | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Provider | AlphaCentric Funds | |||
Manager/Tenure (Years) | Ryan Dunnegan (0) | |||
Website | http://www.AlphaCentricFunds.com. | |||
Fund Information | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Fund Name | AlphaCentric Life Sciences and Healthcare Fund Class C | |||
Category | Health | |||
Sub-Category | Healthcare Sector Equity | |||
Prospectus Objective | Specialty - Health | |||
Inception Date | Nov 29, 2019 | |||
Open/Closed To New Investors | Open | |||
Minimum Initial Investment | 2,500.00 | |||
Minimum Subsequent Investment | 100.00 | |||
Front End Fee | -- | |||
Back End Fee | -- | |||
Dividends and Shares | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Yield | 1.19% | |||
Dividend | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Yield (Forward) | 1.57% | |||
Asset Allocation | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash | 2.03% | |||
Stock | 97.97% | |||
U.S. Stock | 87.57% | |||
Non-U.S. Stock | 10.40% | |||
Bond | 0.00% | |||
U.S. Bond | 0.00% | |||
Non-U.S. Bond | 0.00% | |||
Preferred | 0.00% | |||
Convertible | 0.00% | |||
Other Net | 0.00% | |||
Price History | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -1.98% | |||
30-Day Total Return | -0.92% | |||
60-Day Total Return | 1.10% | |||
90-Day Total Return | -2.47% | |||
Year to Date Total Return | -3.74% | |||
1-Year Total Return | -6.31% | |||
2-Year Total Return | -10.77% | |||
3-Year Total Return | 3.55% | |||
5-Year Total Return | 35.85% | |||
Price | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Closing Price | -- | |||
1-Month Low Price | -- | |||
1-Month High Price | -- | |||
52-Week Low Price | -- | |||
52-Week Low Price (Date) | -- | |||
52-Week High Price | -- | |||
52-Week High Price (Date) | -- | |||
NAV | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Nav | $11.84 | |||
1-Month Low NAV | $11.66 | |||
1-Month High NAV | $12.09 | |||
52-Week Low NAV | $11.32 | |||
52-Week Low NAV (Date) | May 14, 2025 | |||
52-Week High NAV | $13.81 | |||
52-Week High Price (Date) | Sep 19, 2024 | |||
Beta / Standard Deviation | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.78 | |||
Standard Deviation | 20.81 | |||
Balance Sheet | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Total Assets | 34.42M | |||
Operating Ratios | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Expense Ratio | 2.41% | |||
Turnover Ratio | 164.00% | |||
Performance | LYFCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Last Bull Market Total Return | 17.00% | |||
Last Bear Market Total Return | -12.02% | |||